Enhancement of memory network activity in schizophrenia patients by phosphodiesterase-4 (PDE4) inhibitor, roflumilast: A pilot study
These changes provide preliminary support for a cerebral mechanism of action of roflumilast, which includes modulation of brain regions involved in memory known to be impaired in patients with schizophrenia. This data supports existing findings suggesting roflumilast has the potential to be an effective treatment for cognitive impairments in schizophrenia.
Authors
- Peter C.T. Hawkins (ORCID: https://orcid.org/0000-0002-2256-1648)
- James Gilleen (ORCID: https://orcid.org/0000-0003-1095-9058)
- Donni Ann Staley
- Klaudia Stanoch
- Mitul Ashok Mehta
Institutions
- Wellcome Centre for Human Neuroimaging (GB)
- King's College London (GB)
- Mental Health Research UK (GB)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1177/02698811261420098
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00